More Growth Hormone Isn’t Always Better: What Bryan Johnson’s CJC-1295 Experiment Showed

Growth hormone has a particular grip on the longevity imagination. Levels decline with age, and the decline tracks with the things people associate with getting older: slower recovery, softer body composition, less restorative sleep. A whole category of peptides has emerged that promises to push those levels back up. CJC-1295 is one of the more popular options. Bodybuilders use it for muscle and recovery. Biohackers use it for anti-aging. Anti-aging clinics offer it as a flagship protocol.

The premise underneath all of this is intuitive. If growth hormone declines with age, and growth hormone supports the things you want to preserve as you age, then raising growth hormone should be a good idea.

Johnson runs what is arguably the most extensively instrumented personal health protocol in the world. This spring, he ran a ten-day CJC-1295 with DAC experiment on himself, measured a panel of biomarkers before and after, and posted the full results to his audience. The peptide did exactly what it was supposed to do. His growth hormone rose roughly eight-fold, but almost everything else on his panel that you would actually want to improve with age moved in the wrong direction.

What happened to him is a useful window into a frame that gets very little attention in the broader peptide conversation: the difference between raising a number and improving the underlying biology that number is supposed to reflect.

What the CJC-1295 Experiment Actually Measured

CJC-1295 is a synthetic peptide that signals the pituitary to release growth hormone. The version Bryan used, CJC-1295 with DAC (drug affinity complex), is modified so the peptide remains active in the body for days rather than hours. One injection produces a sustained signal. The version without DAC produces a shorter, sharper effect that fades quickly.

Bryan’s protocol was straightforward: two injections over ten days, with a baseline biomarker panel before he started and a follow-up panel at the end. He tracked his sleep through Whoop the entire time.

The intended effect landed clearly. His growth hormone rose roughly eight-fold. By the narrow definition of “did the peptide do what it was supposed to do,” the experiment was a success. The rest of his panel told a different story, and that is where the experiment gets interesting.

Three things moved in directions you would not want them to move.

The first was his metabolic picture. His fasting blood sugar climbed, and a marker that reflects how hard his pancreas was working to keep that blood sugar in range climbed with it. His insulin resistance score, a composite measure of how efficiently his body handles glucose, ticked up as well. None of these moved into a clinically alarming range, but the direction of travel was unambiguous: in ten days, on a peptide that is supposed to support healthy aging, his metabolic health was moving the wrong way.

The second was stress hormone. His morning cortisol rose. Cortisol is supposed to be elevated in the morning to help you wake up and engage with the day, but elevated above your own baseline, over time, is associated with all the things you would expect: poorer sleep, harder recovery, blunted insulin sensitivity. It compounds with the metabolic picture rather than offsetting it.

The third, and the one Bryan flagged as most disruptive in his own experience, was his sleep. His REM sleep dropped substantially, measured as a weekly average through his Whoop. REM is when the brain processes memory, consolidates learning, and does much of the work of overnight recovery. Less REM is one of the more consistent signals of nervous system stress, and it tracks with how he described feeling during the experiment: continuously tired, never fully recovered, like a low-grade jet lag he could not shake.

Bryan stopped the experiment after two doses, before reaching the intended target dose. The full bloodwork panel he posted shows exactly how each marker moved, and it is worth a look.

The Result Most People Will Miss

There is one more thing on his panel worth talking about, and it is the most important finding in the entire experiment. To understand why, it helps to think about growth hormone differently than most peptide content frames it.

Imagine growth hormone as an invitation to a party. The pituitary sends invitations out into the body, and the more growth hormone you have, the more invitations are circulating. By that measure, Bryan threw a great party. Eight times more invitations went out than before.

But invitations are not the party. The party is what happens once people are actually inside: the dancing, the conversations, the connections. In the body, the party is IGF-1. IGF-1 is the downstream messenger that growth hormone signals the liver to release, and it is IGF-1, not growth hormone itself, that does most of the work people associate with growth hormone’s benefits. Protein synthesis. Tissue repair. Lean mass support. Recovery. If growth hormone is the invitation, IGF-1 is what actually happens at the party.

Bryan’s growth hormone rose roughly eight-fold over ten days. His IGF-1 did not move.

Eight times more invitations went out, and the party itself did not change at all.

There are several reasons this might have happened, and none of them are reassuring. The ten-day window may have been too short for IGF-1 to respond, though most protocols would expect movement well within that range. The dose may not have been calibrated for downstream conversion. Or, and this is the explanation the next section turns to, the way the invitations were sent out may have been wrong. The body responds to the pattern of the signal, not just the volume of it. A flood of invitations that all arrive at once, and keep arriving for days, is not the same kind of invitation that a sharp, well-timed pulse delivers.

Whatever the explanation, the frame is what matters. The narrative around growth hormone peptides is almost entirely about pushing the growth hormone number higher. The relevant question is whether higher growth hormone is actually doing the work it is assumed to be doing. In Bryan’s case, on this protocol, in this window, it was not. The invitations went out, and the party stayed exactly the same size.

How You Raise Growth Hormone May Matter More Than Whether You Do

Growth hormone is normally released in pulses. The pituitary produces short, sharp bursts of it several times per day, with the largest pulses occurring during the deepest stages of sleep. Between pulses, levels fall close to zero. The receptors that respond to growth hormone, and the downstream machinery that converts that signal into IGF-1 and other effects, are built around this pulsatile pattern.

Going back to the party metaphor, a good party works in waves. Guests arrive in groups, the energy builds, the room peaks, things taper, the room resets, and another wave arrives. The peaks are what make the party. The rests between them are what make the peaks possible.

A party where the door is propped open and people stream in continuously for ten hours straight does not have peaks. It has a steady, exhausting hum that wears everyone out. The room never resets. The energy never builds because it never falls. By the end, everyone is tired, the music is louder than it needs to be, and nothing meaningful has happened.

That is the difference between pulsatile and sustained growth hormone elevation, and it is the leading explanation for why Bryan's panel looked the way it did. The metabolic costs, the cortisol rise, the disrupted sleep are the kinds of costs you would expect from a body running continuously on a signal it was designed to receive in waves.

So how should someone actually think about growth hormone peptides if pulsatility matters this much? Four variables do most of the work.

Pulsatility is the first: protocols that preserve the body's natural release pattern versus protocols that produce sustained elevation. Dose is the second: restoration-level signaling versus pushing levels well above what the body would ever produce on its own. Duration and washout is the third: designed cycling versus chronic exposure. Monitoring is the fourth: comprehensive baseline and follow-up biomarker panels versus flying blind.

The conservative reading of what physiology seems to want is lower-dose, pulse-preserving, monitored protocols run over longer windows. That is not a claim about which specific peptide or combination is correct. It is a claim about which variables matter. The protocols that get this right are downstream of the principle, and how physicians sequence peptides across different goals is a related question this site has addressed elsewhere.

The honest version of the science here ends with what is still unknown. The mechanistic case for pulsatility is strong. No controlled trial has yet compared sustained-elevation protocols head to head with pulse-preserving protocols for long-term outcomes. The comparative data is not there yet. Anyone making confident claims in either direction is overreaching the evidence.

What This Actually Suggests About Growth Hormone Peptides

None of this is an argument that growth hormone peptides do not work, or that they should not be used.

It is an argument that the goal is not to maximize a number. Restoring growth hormone signaling toward where it was in earlier adulthood is a reasonable aim for many people. Pushing it eight-fold above that, particularly in a way that produces sustained rather than pulsatile elevation, is a different bet entirely. Bryan’s bloodwork is what that different bet looks like when it is measured carefully over ten days.

The thoughtful version of using growth hormone peptides looks different than what Bryan ran. Lower doses, calibrated to restoration rather than supraphysiologic levels. Protocols that preserve pulsatility rather than producing a continuous signal. Designed cycling rather than chronic exposure. And critically, biomarker monitoring that can catch the kind of metabolic drift Bryan caught in himself.

That last point matters more than it might seem. The signals he saw, the rising blood sugar, the climbing insulin resistance, the disrupted sleep, would have been invisible to someone who was not measuring them. The actual hazard of self-experimentation with growth hormone peptides is not that something bad will definitely happen. It is that something can go quietly wrong in your metabolic health, your stress hormones, or your sleep, and you would have no way of knowing. Bryan’s experiment had a good ending only because he was instrumented for it. Most people trying CJC-1295 from gray-market sources are running no panels at all. What physician-guided peptide therapy actually involves, at its core, is the difference between flying blind and being able to see.

What to Watch Next

Bryan closed his thread by saying he plans to retest his bloodwork after a two-week washout. If his markers return to baseline, the growth hormone mechanism is confirmed and the costs he saw were peptide-driven. If they stay elevated, something else was going on. Either way, the field gets useful data.

That posture, holding conclusions loosely, instrumenting carefully, treating costs as real, and updating when the data arrives, is the right one for this entire space. Peptides reward that kind of attention. They punish the opposite.

The question worth asking, at the end of all of this, is not how many invitations you can send. It is whether the party itself is the kind your body actually wants to host.